Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1989-08-28
1990-07-31
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
A61K 3156
Patent
active
049450891
ABSTRACT:
Pharmaceutical compositions useful in the treatment of ophthalmic inflammation and methods of treating ophthalmic inflammation with those compositions are disclosed. The compositions contain a combination of a glucocorticoid and tetrahydrocortexolone. The tetrahydrocortexolone serves to substantially prevent any significant increases in intraocular pressure which might otherwise by experienced by the patient as a side effect of the glucocorticoid component of the compositions. The therapeutic interaction of the two components therefore allows the potent antiinflammatory properties of the glucocorticoids to be utilized without fear of elevating intraocular pressure. A method of preventing increases in intraocular pressure attributable to systemic or topical corticosteroid therapy is also disclosed. That method involves the administration of a pharmaceutical composition containing tetrahydrocortexolone to a patient receiving such therapy.
REFERENCES:
patent: 3449494 (1969-06-01), Lerner
patent: 3474168 (1969-10-01), Schayer
patent: 4383992 (1983-05-01), Lipari
patent: 4617299 (1986-10-01), Knepper
patent: 4686214 (1987-08-01), Boltralik
Mindel et al., "Comparative Ocular Pressure Elevation by Medrysone, Fluorometholone, and Dexamethasone Phosphate", Arch. Oph., vol. 98, pp. 1577-1578 (1980).
Cantrill et al., "Comparison of In Vitro Potency of Corticosteroids with Ability to Raise Intraocular Pressure", Am. Journal of Oph., vol. 79, pp. 103-107 (1975).
Kitazawa, Y., "Increased Intraocular Pressure Induced by Corticosteroids", Am. Journal of Oph., vol. 82, pp. 492-495 (1976).
Southren et al., "Intraocular Hypotensive Effect of a Topically Applied Cortisol Metabolite: 3.alpha., 5.beta.-Tetrahydrocortisol", Investigative Ophthalmology & Visual Science, vol. 28, pp. 901-903 (1987).
Treister et al., "Intraocular Pressure and Outflow Facility", Arch. Ophthal., vol. 83, pp. 311-318 (1970).
Meyer et al., "Influence of Norethynodrel with Mestranol on Intraocular Pressure in Glaucoma", Arch Ophthal., vol. 75, pp. 771-773 (1966).
Lamble et al., "Some Effects of Progestogens, Oestrogens and Androgens on the Ocular Tension of Rabbits and Owl Monkeys", Exp. Eye Res., vol. 26, pp. 599-610 (1978).
Alcon Laboratories Inc.
Arno James A.
Brown Gregg C.
Fay Zohreh A.
Robinson Douglas W.
LandOfFree
Use of tetrahydrocortexolone to prevent elevations in intraocula does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of tetrahydrocortexolone to prevent elevations in intraocula, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of tetrahydrocortexolone to prevent elevations in intraocula will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1398849